Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
RESEARCH TOOLSreports
Holding LQDA?
Track your performance easily
LQDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.60 - $16.99
Previous Close$10.12
Volume567.31K
Average Volume (3M)913.38K
Market Cap
$859.91M
Enterprise Value$655.54M
Total Cash (Recent Filing)$204.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 13, 2025EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding84,636,621
10 Day Avg. Volume816,158
30 Day Avg. Volume913,380
Standard Deviation0.20
R-Squared0.00276
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)7.72
Price to Sales (P/S)55.09
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue41.99
Enterprise Value/Gross Profit44.90
Enterprise Value/Ebitda-6.11
Forecast
1Y Price Target
$26.17Price Target Upside157.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Liquidia Technologies News
PremiumCompany Announcements
Liquidia Corporation’s Q3 2024 Financial Highlights
Bulls Say, Bears Say
Bulls Say
Product DevelopmentL606 offers consistent drug exposure over 24 hours, which is critical for patients and could improve compliance and drug performance.
Regulatory ApprovalThe Supreme Court of the United States has denied UTHR's writ of certiorari request to challenge the prior invalidation of the '793 patent, clearing the path for Yutrepia's launch.
Strategic PartnershipsThe collaboration with Pharmosa Biopharm to develop L606 and expand Liquidia's licensed territory is a strategic move ahead of a future launch.
Bears Say
Legal And Patent IssuesOngoing '327 patent litigation poses a risk to Yutrepia's launch, with unresolved legal challenges potentially impacting the company's strategy.
Market SentimentHigh short interest at 22% of Liquidia's float suggests a lack of confidence among investors, indicating skepticism about the company's near-term prospects.
Regulatory ChallengesThe FDA's decision to delay Yutrepia's final approval until after the expiration of Tyvaso DPI's exclusivity creates significant uncertainty for investors.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $6.60 and its highest was $16.99 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Currently, no data Available
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Mar 13, 2025 which is in 111 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Nov 13, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $0.074.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -$0.38.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 84,636,620 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went down -3.387%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Among the largest hedge funds holding Liquidia Technologies Inc’s share is Farallon Capital Management, L.L.C.. It holds Liquidia Technologies Inc’s shares valued at 33M.
---
Liquidia Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.17 (157.83% Upside)
$26.17 (157.83% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
55.69%
12-Months-Change
Fundamentals
Return on Equity
-150.73%
Trailing 12-Months
Asset Growth
126.52%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
---
LQDA Earnings Call
Q3 2024
0:00 / 0:00
---
LQDA Stock 12 Month Forecast
Average Price Target
$26.17
▲(157.83% Upside)
Technical Analysis
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+29.16%
reiterated a buy rating 9 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +29.16% per trade.
---